XLO News and Press, Xilio Therapeutics Inc.

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced that company management will participate in a fireside chat ...

2026-02-12 02:29:28 ET Read the full article on Seeking Alpha For further details see: Xilio Therapeutics prices $40M stock offering

WALTHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people living with cancer, today announced the pricing of an underwritten offering of pre-funded warrant...

Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway into second quarter of 2027 Achieved development milestone for masked antibody-based p...

2025-11-13 12:25:29 ET More on Xilio Therapeutics Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC - Slideshow Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data a...

Reported late-breaking Phase 2 data at SITC for vilastobart demonstrating a 40% ORR in heavily pretreated patients with MSS mCRC without liver metastases and high plasma tumor mutational burden Presented Phase 1 data at SITC for efarindodekin alfa showing promising monotherapy anti-tumor ...

GRI Bio Inc. (GRI) is expected to report $-1.11 for Q3 2025 Meridian Mining UK Societas (MRRDF) is expected to report $-0.01 for Q3 2025 CaliberCos Inc. (CWD) is expected to report $-0.32 for Q3 2025 BioCorRx Inc (BICX) is expected to report $-0.06 for Q3 2025 Beneficient (BENF) i...

2025-11-11 04:04:03 ET Xilio Therapeutics, Inc. (XLO) Discusses Phase 2 Vilastobart Combination Data and High Plasma TMB as Predictive Biomarker in MSS mCRC November 10, 2025 4:30 PM EST... Read the full article on Seeking Alpha For further details see: Xilio Therapeutics, I...

40% ORR in heavily pre-treated patients with MSS mCRC without liver metastases and with high plasma tumor mutational burden (TMB) Estimate 55% of patients with MSS CRC have high plasma TMB, representing a meaningful population with high unmet need Company to host conference call a...

Preclinical data support best-in-class potential of masked T cell engager programs and platform utilizing Xilio’s ATACR and SEECR formats, including efficient masking, potent anti-tumor activity and broad therapeutic index Phase 1 data for efarindodekin alfa, a tumor-activated IL-1...